Flaxseed lignan secoisolariciresinol diglucoside ameliorates experimental colitis induced by dextran sulphate sodium in mice. (October 2016) - Xu, Jiqu
Highlights: Oral SDG treatment suppressed DSS-induced colon injury. Oral SDG treatment decreased DSS-induced histological changes. Oral SDG treatment inhibited DSS-induced inflammation. Oral SDG treatment decreased colonic mucosal permeability. Abstract: The effect of flaxseed lignan secoisolariciresinol diglucoside (SDG) on ulcerative colitis was examined. Experimental colitis was induced in mice by administering 5% dextran sulphate sodium (DSS). SDG in doses of 100 and 200 mg/kg/day and 5-aminosalicylic acid (positive control) were given orally for 3 days before and during DSS administration. Oral SDG treatment significantly decreased the disease activity index and increased colon length. Histological examination revealed that the oral administration of SDG suppressed DSS-induced erosion, ulceration, crypt abscesses and oedema. Furthermore, colonic myeloperoxidase activity and TNF-α expression declined remarkably following treatment with SDG. Additionally, oral SDG treatment significantly increased the expression of several mucoprotection markers, to include zona occludens-1, Tollip and trefoil factor 3, and thus restored intestinal permeability. These results suggested that oral SDG treatment can alleviate DSS-induced colitis and might be a promising supplement for the amelioration of inflammatory bowel disease.